Showing results (101-110 of 115) with videos related to
Sort By:
Pageof 12
Transplantation and Cellular Therapy|November 12, 2025
Effect of Inflammatory Bowel Disease on Clinical Outcomes of Hematopoietic Cell Transplantation for Inborn Errors of ImmunityRyu Yanagisawa, Satoshi Miyamoto, Yoji Sasahara, et al.JCI Insight|October 26, 2016
Systems biology analysis reveals role of MDM2 in diabetic nephropathyRintaro Saito, Anaïs Rocanin-Arjo, Young-Hyun You, et al.Frontiers in Cardiovascular Medicine|June 10, 2021
Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2)Koki Mise, Mariko Imamura, Satoshi Yamaguchi, et al.Journal of Diabetes Investigation|October 9, 2025
Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study)Munehiro Kitada, Masao Toyoda, Osamu Sekine, et al.BMJ Open Diabetes Research & Care|May 30, 2024
Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3)Asami Ueno, Yasuhiro Onishi, Koki Mise, et al.The Journal of Clinical Investigation|October 19, 2013
AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial functionLaura L Dugan, Young-Hyun You, Sameh S Ali, et al.Diabetes, Obesity & Metabolism|May 2, 2022
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE studySatoshi Miyamoto, Hiddo J L Heerspink, Dick de Zeeuw, et al.Kidney International Reports|March 30, 2026
Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONESatoshi Miyamoto, Hiddo J L Heerspink, Dick de Zeeuw, et al.Cancer|May 20, 2022
First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumorsMasatoshi Takagi, Chitose Ogawa, Tomoko Iehara, et al.Journal of Clinical Immunology|May 21, 2024
Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of ImmunitySatoshi Miyamoto, Daiki Niizato, Dan Tomomasa, et al.Pageof 12